Dynamic Coronary Roadmap for Contrast Reduction

Clinical Trial ID: NCT04085614

Description

The Dynamic Coronary Roadmap is a commercially available product developed by Philips Medical Systems, a Philips Healthcare company. Dynamic Coronary Roadmap is a software medical device intended to provide a real-time and dynamic angiographic roadmap of coronary arteries. The angiographic roadmap is automatically generated from previously acquired coronary angiograms during the same procedure. Dynamic Coronary Roadmap overlays the angiographic roadmap on live 2D fluoroscopic images, thereby assisting the physician in navigating devices, e.g. (guide) wires, catheters, through the coronary arteries. This is a multi-center, prospective, unblinded, stratified 1:1 randomized controlled trial to assess whether using Dynamic Coronary Roadmap reduces the total iodinated contrast volume related to PCI compared to the control group without Dynamic Coronary Roadmap.

Primary objective: • To assess whether using Dynamic Coronary Roadmap reduces the total iodinated contrast volume related to PCI compared to the control group without Dynamic Coronary Roadmap. Secondary objective: • To assess the total number of contrast enhanced cine angiographic X-ray runs (angiograms) related to PCI in the Dynamic Coronary Roadmap and control group


Criteria

Inclusion Criteria: - Subject is undergoing Percutaneous Coronary Intervention (PCI) with a degree of complexity that anticipates the need for more than 25ml of iodinated contrast volume - Subject has signed informed consent - Subject is 18 years of age or older, or of legal age to give informed consent per state or national law Exclusion Criteria: - Subject undergoing emergency PCI - Subject with ST-segment Elevation Myocardial Infarction (STEMI) - Subject with Chronic Total Occlusion (CTO) - Subject undergoing PCI for isolated ostial disease of Left Main Coronary Artery (LMCA) or Right Coronary Artery (RCA) - Subject undergoing PCI with Optical Coherence Tomography (OCT) support - Subject undergoing PCI with rotational or orbital atherectomy - Subject with Chronic Kidney Disease (CKD) stage V (eGFR < 15 ml/min/1.73 m2) - Subject with contrast allergy that cannot be adequately pre-medicated - Subject participates in a potentially confounding drug or device trial during the course of the study. - Subject is under 18 years of age, or pregnant woman, or breast feeding woman, or meets an exclusion criteria according to national law

  • Start Date

    2019-10-01

  • Last Updated

    2020-02-06

  • Sponsor

    Philips Healthcare

  • Condition Name

    Coronary Artery Disease

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.